MidasCare Pharmaceuticals Private Limited – Trademark Portfolio

Entity Type: 03

MidasCare Pharmaceuticals Private Limited holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include RELISPRAY. The owner is based in Goregaon (E), Mumbai.

Lotus Corp Park, Graham Firth Compound

Western Express Highway

Goregaon (E), Mumbai 400063 , IN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

RELISPRAY
RELISPRAY
Registered 2014

Trademark Classifications

MidasCare Pharmaceuticals Private Limited's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does MidasCare Pharmaceuticals Private Limited have?

MidasCare Pharmaceuticals Private Limited has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does MidasCare Pharmaceuticals Private Limited file in?

MidasCare Pharmaceuticals Private Limited files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are MidasCare Pharmaceuticals Private Limited's most well-known trademarks?

MidasCare Pharmaceuticals Private Limited's registered trademark portfolio includes well-known marks such as RELISPRAY. These are among 1 currently registered trademark in the portfolio.

What is MidasCare Pharmaceuticals Private Limited's trademark registration success rate?

MidasCare Pharmaceuticals Private Limited has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.